Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy.
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy.
复制标题
DOI:
10.1038/s41434-021-00300-7
复制
发表时间:
2022-11
期刊:
影响因子:
5.1
通讯作者:
Neubert, Hendrik
中科院分区:
文献类型:
--
作者:
Farrokhi, Vahid;Walsh, Jason;Palandra, Joe;Brodfuehrer, Joanne;Caiazzo, Teresa;Owens, Jane;Binks, Michael;Neelakantan, Srividya;Yong, Florence;Dua, Pinky;Le Guiner, Caroline;Neubert, Hendrik
Duchenne muscular dystrophy (DMD) is a lethal, degenerative muscle disorder caused by mutations in the DMD gene, leading to severe reduction or absence of the protein dystrophin. Gene therapy strategies that aim to increase expression of a functional dystrophin protein (mini-dystrophin) are under investigation. The ability to accurately quantify dystrophin/mini-dystrophin is essential in assessing the level of gene transduction. We demonstrated the validation and application of a novel peptide immunoaffinity liquid chromatography–tandem mass spectrometry (IA-LC-MS/MS) assay. Data showed that dystrophin expression in Becker muscular dystrophy and DMD tissues, normalized against the mean of non-dystrophic control tissues (n = 20), was 4–84.5% (mean 32%, n = 20) and 0.4–24.1% (mean 5%, n = 20), respectively. In a DMD rat model, biceps femoris tissue from dystrophin-deficient rats treated with AAV9.hCK.Hopti-Dys3978.spA, an adeno-associated virus vector containing a mini-dystrophin transgene, showed a dose-dependent increase in mini-dystrophin expression at 6 months post-dose, exceeding wildtype dystrophin levels at high doses. Validation data showed that inter- and intra-assay precision were ≤20% (≤25% at the lower limit of quantification [LLOQ]) and inter- and intra-run relative error was within ±20% (±25% at LLOQ). IA-LC-MS/MS accurately quantifies dystrophin/mini-dystrophin in human and preclinical species with sufficient sensitivity for immediate application in preclinical/clinical trials.
登录
查看更多内容
影响因子:
1.8
作者:
Piccoli,Steven;Mehta,Devangi;Yang,Tong-Yuan
通讯作者:
Yang,Tong-Yuan
影响因子:
3.4
作者:
Ghosh R;Gilda JE;Gomes AV
通讯作者:
Gomes AV
影响因子:
4.4
作者:
Anderson, NL;Anderson, NG;Pearson, TW
通讯作者:
Pearson, TW
影响因子:
9.3
作者:
Neubert, Hendrik;Shuford, Christopher M.;Ackermann, Bradley L.
通讯作者:
Ackermann, Bradley L.
影响因子:
11.2
作者:
Mendell, Jerry R.;Shilling, Chris;Weiss, Robert B.
通讯作者:
Weiss, Robert B.